IQWiG in dialogue
Assessing benefit and replication of study results
Methodological aspects were the focus of the programme: framework conditions and methodological procedure in relation to IQWiG's benefit assessment, the meaning of the "2-study rule" in evaluating study results and the methodological foundations for assessing benefit.
- Three years of benefit assessments in IQWiG - taking stock PD Dr. Stefan Lange
- Introduction to the topic "Replication of study results? Prof. Dr. Ralf Bender
- Pivotal studies: Why do the regulatory authorities usually require that study results be replicated? Dr. Armin Koch (Federal Institute for Drugs and Medical Devices, BfArM)
- Decision approaches and statistical foundations for the cost-benefit assessment in comparison with confirmatory approval studies Friedhelm Leverkus (Pfizer)